Related Experiment Video
Updated: Jun 2, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Pyridoxine-dependent epilepsy: an under-recognised cause of intractable seizures
Nune S Yeghiazaryan1, Federico Zara, Giuseppe Capovilla
1Armenian Republican Epilepsy Centre Erebouni, Yerevan State Medical University, Yerevan, Armenia. ynune@yahoo.com
Insights
Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder causing severe infant seizures. Early pyridoxine treatment is crucial for managing this condition, even when other therapies fail.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder.
- It causes intractable seizures in neonates and infants, often resistant to standard anti-epileptic drugs.
Observation:
- Patients with PDE typically respond well to pyridoxine administration.
- Seizure types vary, with status epilepticus being common.
- Electroencephalographic and neuroimaging findings are not specific for PDE.
Findings:
- Elevated urinary α-aminoadipic semialdehyde is a reliable biomarker for PDE.
- Mutations in the ALDH7A1 gene are found in most PDE patients.
- ALDH7A1 encodes α-aminoadipic semialdehyde dehydrogenase.
Implications:
- Early consideration of a pyridoxine trial is paramount for infants with intractable early-onset seizures.
- Identifying PDE is critical for appropriate and timely treatment.
- Intellectual disability is a frequent long-term outcome if not treated promptly.
Abstract:
Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder causing intractable seizures in neonates and infants. PDE patients are typically resistant to anti-epileptic treatment but respond to the administration of pyridoxine. Different seizure types have been reported in PDE, and episodes of status epilepticus are common. Electroencephalographic or neuroimaging abnormalities are not pathognomonic for this disorder. Intellectual disability is frequent at the follow-up. Recently, elevated urinary α-aminoadipic semialdehyde has been shown to be a reliable biomarker of this disorder, and mutations in the ALDH7A1 gene, encoding α-aminoadipic semialdehyde dehydrogenase, have been demonstrated in the large majority of PDE patients. However, early consideration of a pyridoxine trial remains the most important issue in a neonate or in an infant with intractable early onset seizures.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures l: Introduction
Epilepsy ll: Types
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

